Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HPS2-THRIVE: Niacin/Laropiprant for Cardiovascular Event Reduction
NCT00461630Phase 3Completed
- Sponsor
- University of Oxford
- Start
- Jan 2007
- Primary completion
- Oct 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of laropiprant + niacin in cardiovascular disease (CVD), sponsored by University of Oxford. Started Jan 2007; status: completed.
02
Drugs
laropiprant + niacin
03
Conditions
cardiovascular disease (CVD)
Beyond the preview
Go deeper on NCT00461630.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00461630.